Month: May 2022

Orphazyme A/S in restructuringCompany announcementNo. 24/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355  KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and assumed liabilities estimated to equal approximately USD 5.2 million The majority of Orphazyme’s approximately 20 current employees will become employees at KemPharm KemPharm intends to continue to pursue approval of arimoclomol as a treatment option for NPCOrphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC), announces today that it has signed an agreement to sell substantially all of the Company’s assets and business activities...

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  AttachmentPrimary insider notification form

Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapyLatest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone Further analysis, following U.S. Food and Drug Administration recommendations on censoring rules, showed mPFS increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasonePARIS, May 15, 2022. Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination...

This launch coincides with the inaugural IgAN Awareness Day STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease. IgANConnect.com provides individuals who have just been diagnosed with IgA nephropathy, those who have been living with the disease for many years, and caregivers the tools to help understand and manage IgA nephropathy. The complimentary IgAN Connect Facebook page provides an environment where individuals living with the disease are encouraged to explore educational and motivational resources alongside other members of the community. “As a rare and chronic autoimmune disease with...

VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or “VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) provides this bi-weekly default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced on April 29, 2022 that it had applied for a management cease trade order (“MCTO”) with the applicable securities regulatory authorities in Canada on the basis that the Company’s audited annual financial statements and accompanying management’s discussion and analysis for the fiscal year ended December 31, 2021 (the “Annual Filings”) would not be filed by the applicable filing deadline of May 2, 2022 (the “Default Announcement”). The Company announced that the MCTO was issued...

VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) — Billy Goat Brands Ltd. (“GOAT” or the “Company”) (CSE: GOAT) (OTCQB: BGTTF) (FRA: 26B), a venture capital platform focused on identifying, sponsoring and incubating high-potential companies in the ocean economy, is pleased to announce it has added Mr. Lawrence Hay to its Board of Directors. Mr. Hay is an officer and director of a variety of private and public companies and has extensive experience structuring and financing companies within the clean energy and ESG industries. Further, former Chief Operating Officer and founding director of the Company, Kris Dahl, has stepped down and also resigned from the Board of Directors effective immediately. The Company would like to thank Mr. Dahl for his valuable contributions to date and wishes him the best of luck with his future...

CALGARY, Alberta, May 13, 2022 (GLOBE NEWSWIRE) — Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) is pleased to announce that all of the motions put forward at its annual meeting of shareholders held on May 13, 2022 (the “Meeting”) were approved by its shareholders. A total of 28,956,760 common shares in the capital of the Company, representing approximately 84.00% of the issued and outstanding common shares, were represented in person or by proxy at the Meeting. All eight director nominees proposed by management were elected. Proxies and in person votes were received as follows:  Votes For % Votes Withheld %Glen Roane 27,802,088 96.14 1,115,807 3.86Catherine Best 26,639,220 92.12 2,278,675 7.88David Bronicheski 28,532,933 98.67 384,962 1.33William Derwin 28,531,856 98.67 386,038 1.33Stephen...